NMI (NASDAQ:NMIH – Get Free Report) is scheduled to announce its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $1.10 per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.
NMI Stock Up 0.5 %
NMI stock opened at $36.96 on Tuesday. NMI has a 1-year low of $27.00 and a 1-year high of $42.49. The firm’s fifty day simple moving average is $40.41 and its 200-day simple moving average is $36.68. The company has a current ratio of 0.67, a quick ratio of 0.67 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $2.94 billion, a P/E ratio of 8.76, a P/E/G ratio of 0.84 and a beta of 1.13.
Insider Activity
In other news, insider William J. Leatherberry sold 3,000 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $40.07, for a total value of $120,210.00. Following the sale, the insider now owns 153,689 shares of the company’s stock, valued at $6,158,318.23. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.40% of the company’s stock.
Wall Street Analyst Weigh In
NMI Company Profile
NMI Holdings, Inc provides private mortgage guaranty insurance services in the United States. The company offers mortgage insurance services, such as primary and pool insurance; and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, internet-sourced lenders, and other non-bank lenders.
Featured Articles
- Five stocks we like better than NMI
- Upcoming IPO Stock Lockup Period, Explained
- Intel: Is Now the Time to Be Brave?Â
- Following Congress Stock Trades
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What Are Growth Stocks and Investing in Them
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for NMI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NMI and related companies with MarketBeat.com's FREE daily email newsletter.